Why Is ABSCI CORP (ABSI) Stock Down Today?

Absci Corp (ABSI) shares fell 9.21% to $9.19 on Wednesday, driven by third-quarter revenues that came in significantly below analyst expectations. The company reported revenue of $304,000, a figure that missed consensus estimates by $280,000.

What Happened

The stock reaction followed the release of Absci's third-quarter financial results, which disclosed a GAAP loss per share of $0.19, in line with the consensus estimate of $0.20. Revenue declined 21.1% year over year. The company stated that its cash, equivalents, and marketable securities balance of $173.7 million as of September 30 is sufficient to fund operating plans into the second half of 2028.

Management also announced the appointment of Gerry Muhle as Chief Commercial Officer to build brands for ABS-201 and the broader pipeline. The company noted that the ABS-201 HEADLINE trial is progressing on track, with 13-week interim proof-of-concept data for pattern hair loss anticipated next month. Additionally, Absci filed an automatic mixed securities shelf registration with the SEC.

What The Data Shows

The stock opened at $9.90, a 2.2% gap down from the prior close of $10.12. The session high was $9.96 at 7:25 AM ET, while the session low reached $8.96 at 9:30 AM ET. Volume stood at 0.9 million shares, which is 0.3 times the three-month daily average.

Fundamentals show a market cap of $1.7 billion with a trailing twelve-month EPS of -$0.80. Revenue has declined 62.3% over the trailing twelve months. The stock carries a beta of 2.19 and a 52-week range of $2.24 to $12.54. Over the last eight sessions, the stock had moved up 4.4% from $9.69 to $10.12 before the current decline. The 52-week tape recorded two fresh highs and three fresh lows on November 12, 2026.

What To Watch

Investors will monitor upcoming data releases, specifically the anticipated 13-week interim proof-of-concept data for pattern hair loss expected next month. Coverage from nine stories across five sources in the last 36 hours indicates continued focus on the company's clinical progress and commercial strategy.